Trethera Corporation and KYAN Therapeutics announce collaboration to develop artificial intelligence-driven optimization of solid cancer combination therapy
Los Angeles//Singapore, October 25, 2018 /PRNewswire/ — Trethera Corporation (Trethera),a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer,and KYAN Therapeutics, an artificial intelligence-based drug development firm, announced an agreement to collaborate on preclinical studies evaluating up to four different tumor types beginning this year leveraging their unique expertise to […]